#TeamVeracyte is in Washington, DC this weekend for the American Urological Association’s (#AUA2026) Annual Meeting, May 15–18. Stop by Booth 3405 to learn how our Decipher tests bring insight to prostate and bladder cancer care. 🔹#DecipherProstate: Delivering genomic information to support clinical decision-making across the prostate cancer continuum 🔹#DecipherBladder: Molecular subtyping that provides deep biological insight to support more individualized bladder cancer care 🔹#DecipherGRID: Proprietary research-use-only database is designed to help advance the understanding of urologic cancers at the molecular level | Resources | 🔗 Event details and full presentation schedule - veracyte.com/company/event/a… #AUA26 #DecipherUrologicCancers #UrologicCancer #ProstateCancer #BladderCancer #PrecisionMedicine #CancerDiagnostics

Swing by! #DecipherProstate by @Veracyte , Inc. is at the #ACRO2026 in Orlando, FL. Visit booth 302 today or tomorrow to learn how we’re helping transform #ProstateCancer care! #UrologicCancer #PrecisionMedicine

New study: Post-prostatectomy patients with #DecipherProstate high risk scores showed significantly higher rates of biochemical recurrence and adverse pathology. Scores >0.85 were associated with the highest recurrence incidence. #ProstateCancer Read more: pubmed.ncbi.nlm.nih.gov/4106…

High-risk localized prostate cancer represents a heterogeneous group at the molecular level. In a recent analysis of samples from the phase 3 NRG/RTOG 0521 trial, #DecipherProstate delivered independent prognostic insights beyond traditional clinical factors, helping assess metastasis-free survival (MFS) and distant metastasis risk in patients with high-risk, nonmetastatic prostate cancer. Importantly, a subset of patients with very high Decipher scores (>0.85) had a distinctly worse prognosis: more than a 2-fold higher risk of MFS events compared with low/intermediate scores, and the highest 10-year cumulative incidence of distant metastasis. These findings underscore Decipher’s value in identifying high-risk patients who may benefit from intensified therapy and in guiding personalized treatment decisions. | Resources | 🔹Read the abstract: lnkd.in/e8XwwUUa 🔹Explore Decipher Prostate: lnkd.in/gf--GyzM #DecipherUrologicCancers #ProstateCancer #PrecisionMedicine #UrologicOncology #GenomicTesting #PersonalizedMedicine #ClinicalResearch #Biotech #Urology #CancerDiagnostics #NRGOncology

#DecipherProstate by Veracyte was incorporated in a predictive model for lymph node involvement in prostate cancer. Decipher improves risk stratification and helps identify patients who may benefit from extended node dissection at radical prostatectomy.

A study of 140K men with nonmetastatic #ProstateCancer showed that over 60% with high Decipher scores (>0.85) and AJCC grade IIC–IIIC may benefit from targeted therapies. Findings support #DecipherProstate by @Veracyte testing to guide personalized treatment.

NEW RESEARCH: Focal therapy is a treatment option for select patients with prostate cancer, yet ~20% experience early failure. Our #DecipherProstate genomic classifier has been proposed as a more effective predictor of early recurrence compared to traditional clinical indicators. | KEY FINDINGS | In a pooled analysis of data from a phase II trial and a prospective cohort, higher Decipher scores were significantly associated with an increased risk of post-focal therapy recurrence. This suggests Decipher's utility in identifying patients who may benefit more from:  🔹 Radical treatment approaches   🔹 Closer monitoring protocols    🔗 Read the full article: sciencedirect.com/science/ar…      #FocalTherapy #ProstateCancer #PrecisionMedicine #DecipherUrologicCancers #GenomicTesting #ClinicalResearch #UrologicOncology #PersonalizedMedicine #CancerTreatment

📣 The #DecipherProstate Metastatic Genomic Classifier is now available to select clinical sites through an early access program, with broader availability in June 2025. #OncologyInnovation #PrecisionMedicine Learn more: investor.veracyte.com/news-r… Note: veracyte.com/cautionary-note…

Veracyte’s Decipher Team is delighted that UroToday has created a Center of Excellence for #DecipherProstate. Visit the page to see how urology KOLs use genomic testing across the spectrum of prostate cancer to help personalize treatment planning.

Data from an analysis of the STAMPEDE trial highlights the important role of #DecipherProstate to provide clinicians with insights that can help ensure their patients receive the therapy they need and is right for them. Read more linkedin.com/pulse/mens-heal… #MensHealthAwarenessMonth

New article about #DecipherProstate & the Phase III, multi-center, randomized STAMPEDE clinical trial, offering insights into how our test is demonstrating to be the first molecular biomarker to predict #docetaxel sensitivity in advanced #prostatecancer. journals.lww.com/oncology-ti…

Find us at the Annual Meeting of the Northeastern Section of the AUA in Montreal, Canada! Swing by our booth to chat with our team about how @Veracyte’s #DecipherProstate can empower your treatment planning with clarity and confidence.

Check out our new patient-focused website page, designed to help answer questions your patients may have about @Veracyte's #DecipherProstate testing. shorturl.at/7b8j8

ICYMI: @Veracyte's #DecipherProstate is the only gene expression test to receive a Simon Level 1B evidence rating in the 2024 NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for #ProstateCancer. Learn more at the link below:

Check out this insightful webinar hosted by @PCFNews, in which the use of biomarkers like @Veracyte's #DecipherProstate are discussed, including how they can help shape #ProstateCancer treatment planning. vimeo.com/894679154/a155d36c…

Veracyte's #Decipher Team will be at the Solaris Health Physician Retreat in Miami, Florida, from January 19th-20th. Swing by our booth to discover how our #DecipherProstate test is informing #prostatecancer patient care. #SolarisHealth

Join us at 'Urology on the Beach' hosted by the Desai Sethi Urology Institute @dsui_miami_uro in Miami, Florida January 19th-21st @Veracyte's #Decipher will be there to discuss how our #DecipherProstate test can help inform #ProstateCancer treatment decisions #UrologyOnTheBeach

ICYMI: A recent video from @UroToday centers around two actively accruing phase 3 randomized clinical trials: NRG GU-010 (GUIDANCE) and NRG GU-009 (PREDICT-RT). @Veracyte's #DecipherProstate test is required for randomization. Check out the new video!

We are proud to announce that @Veracyte's  #Decipher Prostate testing will be featured in seven posters at the 2023 Society of Urologic Oncology meeting. If you are here, stop by our booth to learn more about #DecipherProstate. #ProstateCancer #SUO23 @UroOnc

ICYMI: A new video from UroToday provides a comprehensive overview of the performance of #DecipherProstate in a post-hoc analysis of the phase 3 RCT NRG Oncology/RTOG 01-26. Check out the video here: urotoday.com/video-lectures/…